Modified envelope glycoproteins to retarget retroviral vectors.
A conceptual breakthrough in gene therapy would be gene transfer vector that could be systemically applied, allowing targeted gene transfer into a predetermined cell type. The host range of a retroviral vector is determined by the interaction of the viral envelope glycoprotein (Env) and the retrovirus receptor on the surface of the host cell. In this review, we describe the current efforts to engineer targeted envelope glycoproteins, which can be incorporated into retroviral particles and are capable of delivering genes in a highly specific manner.
Haynes
Catherine
C
Institute for Biomedical Research, Georg-Speyer Haus, Paul-Ehrlich-Str. 42-44, D-60596 Frankfurt/Main, Germany. schnierle@em.uni-frankfurt.de
Erlwein
Otto
O
Schnierle
Barbara S
BS
D000818:Animals; D005822:Genetic Vectors; D006801:Humans; D008562:Membrane Glycoproteins / Q000235:genetics*; D012190:Retroviridae / Q000235:genetics*; D014759:Viral Envelope Proteins / Q000235:genetics*
D008562:Membrane Glycoproteins; D014759:Viral Envelope Proteins